Am J Psychiatry 158:518-526, April 2001
© 2001 American Psychiatric Association
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Miranda Chakos, M.D.,
Jeffrey Lieberman, M.D.,
Elaine Hoffman, Ph.D.,
Daniel Bradford, M.D., and
Brian Sheitman, M.D.
OBJECTIVE: The authors conducted a review and meta-analysis of studies that compared the efficacy and tolerability of typical and second-generation antipsychotics for patients with treatment-resistant schizophrenia. METHOD: A systematic search revealed 12 controlled studies (involving 1,916 independent patients), which were included in the review. For the seven studies that compared clozapine to a typical antipsychotic, a meta-analysis was performed to examine clozapine’s effects on overall psychopathology, response rate, extrapyramidal symptoms, and tardive dyskinesia. RESULTS: The meta-analysis confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate. Clozapine also conferred benefits on the sickest treatment-resistant schizophrenic patients. Patients treated with olanzapine also had more favorable outcomes with regard to categorical response and compliance rates. CONCLUSIONS: In the aggregate, the results of a meta-analysis indicated that clozapine exhibits superiority over typical antipsychotics in terms of both efficacy (as measured by improvement in overall psychopathology) and safety (in terms of reduced extrapyramidal side effects). However, the magnitude of the clozapine treatment effect was not consistently robust. Efficacy data for other second-generation antipsychotics in the treatment of patients with refractory schizophrenia were inconclusive. There is, therefore, a growing need to consider new and different treatment strategies, whether they be adjunctive or monotherapeutic, for schizophrenia that continues to be resistant or only partially responsive to treatment.
This article has been cited by other articles:
|
|
|
|
 
M. S. Swartz
Introduction to the CATIE Special Section
Psychiatr Serv,
May 1, 2008;
59(5):
497 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv,
May 1, 2008;
59(5):
500 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Arbuckle, M. J. Gameroff, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Brief Reports: Psychiatric Opinion and Antipsychotic Selection in the Management of Schizophrenia
Psychiatr Serv,
May 1, 2008;
59(5):
561 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Barbui, A. Signoretti, S. Mule, M. Boso, and A. Cipriani
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Schizophr Bull,
April 23, 2008;
(2008)
sbn030v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Schizophr Bull,
April 2, 2008;
(2008)
sbn019v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Owens
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Advan. Psychiatr. Treat.,
January 1, 2008;
14(1):
17 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
6 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. W. Lewis, T. R. E. Barnes, L. Davies, R. M. Murray, G. Dunn, K. P. Hayhurst, A. Markwick, H. Lloyd, and P. B. Jones
Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia
Schizophr Bull,
October 1, 2006;
32(4):
715 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1069 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Focus,
September 1, 2006;
4(4):
539.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Haddad and O. Niaz
What works in schizophrenia: Depot preparations may improve outcomes
BMJ,
August 12, 2006;
333(7563):
353 - 353.
[Full Text]
|
|
|
|
|
|
|
A. H. Fanous and K. S. Kendler
Genetic Heterogeneity, Modifier Genes, and Quantitative Phenotypes in Psychiatric Illness: Searching for a Framework
Focus,
August 1, 2006;
4(3):
423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tandon and H. A. Nasrallah
Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses.
Arch Gen Psychiatry,
August 1, 2006;
63(8):
935 - 937.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses--Reply
Arch Gen Psychiatry,
August 1, 2006;
63(8):
937 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lamberti, D. Olson, J. F. Crilly, T. Olivares, G. C. Williams, X. Tu, W. Tang, K. Wiener, S. Dvorin, and M. B. Dietz
Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine
Am J Psychiatry,
July 1, 2006;
163(7):
1273 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Bai, C.-C. Lin, J.-Y. Chen, C.-Y. Lin, T.-P. Su, and P. Chou
Association of Initial Antipsychotic Response to Clozapine and Long-Term Weight Gain
Am J Psychiatry,
July 1, 2006;
163(7):
1276 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Shaw, A. Sporn, N. Gogtay, G. P. Overman, D. Greenstein, P. Gochman, J. W. Tossell, M. Lenane, and J. L. Rapoport
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison.
Arch Gen Psychiatry,
July 1, 2006;
63(7):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. McEvoy, J. A. Lieberman, T. S. Stroup, S. M. Davis, H. Y. Meltzer, R. A. Rosenheck, M. S. Swartz, D. O. Perkins, R. S.E. Keefe, C. E. Davis, et al.
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Am J Psychiatry,
April 1, 2006;
163(4):
600 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Am J Psychiatry,
April 1, 2006;
163(4):
611 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Honer, A. E. Thornton, E. Y.H. Chen, R. C.K. Chan, J. O.Y. Wong, A. Bergmann, P. Falkai, E. Pomarol-Clotet, P. J. McKenna, E. Stip, et al.
Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia
N. Engl. J. Med.,
February 2, 2006;
354(5):
472 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Fanous, E. J. van den Oord, B. P. Riley, S. H. Aggen, M. C. Neale, F. A. O'Neill, D. Walsh, and K. S. Kendler
Relationship Between a High-Risk Haplotype in the DTNBP1 (Dysbindin) Gene and Clinical Features of Schizophrenia
Am J Psychiatry,
October 1, 2005;
162(10):
1824 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1209 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. West, J. E. Wilk, M. Olfson, D. S. Rae, S. Marcus, W. E. Narrow, H. A. Pincus, and D. A. Regier
Patterns and Quality of Treatment for Patients With Schizophrenia in Routine Psychiatric Practice
Psychiatr Serv,
March 1, 2005;
56(3):
283 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Focus,
January 1, 2004;
2(1):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, G. Tollefson, M. Tohen, A. I. Green, R. E. Gur, R. Kahn, J. McEvoy, D. Perkins, T. Sharma, R. Zipursky, et al.
Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Am J Psychiatry,
August 1, 2003;
160(8):
1396 - 1404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pickar and J. J. Bartko
Effect Size of Symptom Status in Withdrawal of Typical Antipsychotics and Subsequent Clozapine Treatment in Patients With Treatment-Resistant Schizophrenia
Am J Psychiatry,
June 1, 2003;
160(6):
1133 - 1138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Menzin, L. Boulanger, M. Friedman, J. Mackell, and J. R. Lloyd
Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program
Psychiatr Serv,
May 1, 2003;
54(5):
719 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Thieda, S. Beard, A. Richter, and J. Kane
An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia
Psychiatr Serv,
April 1, 2003;
54(4):
508 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. WILLIAMS, G. NEWTON, K. ROBERTS, S. FINLAYSON, and C. BRABBINS
Clozapine-resistant schizophrenia: a positive approach
The British Journal of Psychiatry,
September 1, 2002;
181(3):
184 - 187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Goff
A 23-Year-Old Man With Schizophrenia
JAMA,
June 26, 2002;
287(24):
3249 - 3257.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Pal
Patients with schizophrenia found that clozapine improved their wellbeing without resulting in extrapyramidal motor side effects
Evid. Based Ment. Health,
November 1, 2001;
4(4):
125 - 125.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
